Leaflet MYDRANE 0.2mg / 3.1mg / 10mg / ml solution for injection


Indicated for: nasal congestion; rhinitis

Route of administration: injectable

Substance: tropicamide + phenylephrine + lidocaine (mydriatic + adrenergic decongestant + local anesthetic)

ATC: S01FA56 (Sensory organs | Mydriatics and cycloplegics | Anticholinergics)

Tropicamide+phenylephrine+lidocaine is a combination of medications used in ophthalmology for pupil dilation (mydriasis) and local anesthesia during diagnostic or surgical procedures. Tropicamide is a muscarinic receptor antagonist that relaxes the iris muscles, phenylephrine is an alpha-adrenergic agonist that contracts the iris dilator muscles, and lidocaine is a local anesthetic that reduces pain.

This combination is administered as ophthalmic drops, as directed by a physician. It is commonly used in fundus examinations, cataract surgery, or other ophthalmic interventions.

Common side effects include a burning or stinging sensation in the eye, dry eyes, and temporary photophobia. In rare cases, allergic reactions or temporary increases in intraocular pressure may occur.

Tropicamide+phenylephrine+lidocaine is an effective and safe combination for use in ophthalmology, helping to improve patient comfort and facilitate medical procedures.

General data about MYDRANE 0.2mg / 3.1mg / 10mg / ml

  • Substance: tropicamide + phenylephrine + lidocaine
  • Date of last drug list: 01-05-2026
  • Commercial code: W62116002
  • Concentration: 0.2mg / 3.1mg / 10mg / ml
  • Pharmaceutical form: solution for injection
  • Quantity: 20
  • Product type: original
  • Price: 817.61 RON
  • Prescription restrictions: P-RF - Medicines prescription that is retained in the pharmacy (not renewable).

Marketing authorisation

  • Manufacturer: DELPHARM TOURS - FRANTA
  • Holder: LABORATOIRES THEA S.A.S. - FRANTA
  • Number: 13579/2020/01
  • Shelf life: 3 years